- Home
- SGLY vs PTIX Comparison
SGLY vs PTIX Comparison
Compare SGLY & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | PTIX |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.0M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SGLY | PTIX |
|---|---|---|
| Price | $0.63 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 571.0K | 92.7K |
| Earning Date | 02-18-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,619,679.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $1.12 |
| 52 Week High | $5.49 | $14.28 |
Technical Indicators
Market Signals| Indicator | SGLY | PTIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 37.24 |
| Support Level | $0.45 | $1.12 |
| Resistance Level | $0.67 | $1.68 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 83.35 | 35.96 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.